Nilmat (Nilotinib)

Nilotinib, the active ingredient in Nilmat, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia, particularly in patients whose disease is driven by the Philadelphia chromosome.\n\nGNH India supplies Nilmat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Nilmat belongs to the tyrosine kinase inhibitor class and is used in diseases driven by the BCR‑ABL fusion protein.\n\n- Chronic myeloid leukemia (chronic phase): provides disease control by suppressing leukemic cell proliferation.\n- Philadelphia chromosome‑positive CML: achieves targeted inhibition of the BCR‑ABL kinase.\n- CML after resistance or intolerance to prior therapy: offers an alternative therapeutic option when other TKIs are unsuitable.

Common Side Effects:\n- Nausea\n- Rash\n- Diarrhea\n- Fatigue\n\nSerious or Rare Side Effects:\n- QT interval prolongation\n- Pancreatitis\n- Severe liver injury

Nilmat requires careful monitoring and patient education before and during therapy.\n\n- Cardiac monitoring: obtain baseline ECG and repeat periodically to detect QT prolongation.\n- Liver function: assess hepatic enzymes before initiation and regularly thereafter.\n- Hematology: perform complete blood counts to monitor for neutropenia or thrombocytopenia.\n- Drug interactions: avoid concomitant strong CYP3A4 inhibitors and QT‑prolonging agents.\n- Storage: Store at room temperature: keep in the original container, protect from moisture and light.

Nilmat may interact with several medicines that affect its metabolism or cardiac safety.\n\nMajor Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)\n- QT‑prolonging drugs (e.g., amiodarone, sotalol)\n- Antacids containing aluminum or magnesium\n\nModerate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., erythromycin)\n- Antihypertensive agents (may require dose adjustment).